Signal Genetics, Inc. (MGEN)
(Delayed Data from NSDQ)
$2.83 USD
+0.05 (1.80%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.82 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Viridian Therapeutics, Inc. [MGEN]
Reports for Purchase
Showing records 1 - 20 ( 96 total )
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
When "002" Is Greater Than "001"; MGEN Advancing VRDN-002, HZNP Read-Through
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
In-Licensing of Xtend Antibody Technology Announced; Reiterate Neutral Rating
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Moving Beyond SOLAR Winds; Reiterate Neutral Rating
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
New Direction Marked by Acquisition of Viridian Therapeutics; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Preliminary SOLAR Not Expected to Be Compelling; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initial Cobo/CTCL Ph2 SOLAR Data Lacks Compelling Results; Focus on MRG-229/IPF
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
New CEO Positive for Potential Near-Term Deal Making; Reiterate Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Recap; Pipeline Forging Ahead Despite COVID-Related Delays
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SOLAR Penetrates Through Negative Impacts in 2Q20; Reiterate Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cobo Nabs Orphan Drug Designation in ATLL; Next Up Potential Meeting with FDA
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Promising New Preclinical Data for MRG-229 in IPF
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1; COVID-19 Impact Potentially Delays Several Clinical and Regulatory Events
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SOLAR Isn?t Shielded From COVID-19 So Expect Topline Data to Take Longer; Reiterate Buy and $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Streamlined Strategy Is Poised to Deliver Several Milestones in 2020; Reiterate Buy and $5 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY19: Cash Runway Into Q3:21; Cobomarsen/CTCL Ph2 Enrolled - Topline Q3:20
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Viridian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Emerging Pharma: Upcoming Material Catalysts in Companies with Plenty of Cash
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L